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  VISUAL EVOKED  POTENTIALS  IN  DIABETES MELLITUS 
   Neelambikai.N, Navurang.S*, Coimbatore Medical College, Coimbatore   
ABSTRACT 
 BACKGROUND: Visual evoked potentials are electrical potential differences recorded from the 
scalp in response to visual stimuli. They  are  useful for investigating  the physiology  and  the 
pathophysiology of the human visual system including visual pastways and visual cortex.They 
can  be used  effectively  to study  both  normal and abnormal functions in  the  field of research. 
AIMS AND OBJECTIVES: To study the VEP responses in type 1, type 2 diabetic patients  and 
controls. To compare the VEP responses in type 1 and type 2 diabetics. To assess the correlation 
between the duration of diabetes and wave patterns of VEP in type 1 and type 2 diabetics.To 
evaluate the association between the glycemic control and wave patterns of VEP in type 1 and 
type 2 diabetics.To compare the VEP responses in type 1 and type 2 diabetics in relation to 
glycemic control and duration of diabetes. MATERIALS AND METHODS: STUDY DESIGN: 
Combined cross sectional and case control study. This study was carried out in the Research 
laboratory of the Department of Physiology, Coimbatore medical college, Coimbatore. The study 
was approved by ethical committee.The study was carried out after explaining the procedure in 
detail and getting informed consent from the diabetic patients and normal subjects. A total of 80 
subjects were included in the study of which 40 were diabetics ( 20 type 1 and 20 type 2) and 40 
were controls.They were of 30 -70 yrs of age group.EXCLUSION CRITERIA: Diabetic patients 
with retinopathy, glaucoma, hypertension and cataract were excluded from the study.Pattern shift 
visual evoked potential test was performed in a specially equipped electrodiagnostic procedure 
room.The patients were seated comfortably one meter away pattern – shift screen. Subjects were 
placed in front of a black and white checker board pattern displayed on a video monitor. The 
electrodes were placed using conduction jelly after thoroughly cleaning the area. Recording 
electrode was placed at Oz, reference electrode was placed at Fz  and  ground electrode placed at 
M1   position. Everytime,the pattern changes, patient’s visual system generates an electrical 
response which was detected and recorded by surface electrodes. The patient was asked to focus 
his gaze on to the center of the screen. Each eye was tested separately. RESULTS: One way 
ANOVA and  Student ‘t’test were used to asses the statistical significance. All data is expressed 
as mean  ± SD. The mean value of P100 latency was significantly delayed in type 1and 2 diabetics 
as compared to controls (Pvalue :0.007 left eye,0.030 right eye). There was no statistically 
significant difference found between type 1 and 2 diabetics.The mean value of P100 latency was 
significantly prolonged in diabetics whose HbA1C is >7 % and with increased duration of 
diabetes. There was no statistically significant difference found between type 1 and 2 diabetics in 
relation to glycemic control and duration of disease . CONCLUSION: The delayed P100  latencies 
which were recorded in the absence of retinopathy are indicative of anterior visual pathway 
affection in diabetics. Therefore, VEP should  be considered as a valid method for detecting  
prediabetic retinopathy, which could contribute greatly to the prevention of diabetic retinopathy 
and its complications. 
KEYWORDS: 
          Visual evoked potential, Diabetes mellitus, Diabetic retinopathy. 
 Introduction 
Diabetes mellitus is a heterogenous  group of  metabolic disorders characterized  
by chronic hyperglycemia  with  disturbances of carbohydrate, fat  and  protein 
metabolism  resulting  from defects in insulin secretion, insulin  action  or  both. 
The majority of cases of diabetes fall in to two broad etiopathogenetic categories  
 which are type 1 and type 2 diabetes.  
Type 1 diabetes is the  form of  disease  primarily  due to  beta cell destruction, 
which  requires  insulin for survival. It  is  characterized  by  the  presence of   auto  
antibodies  like  anti-islet cell or  anti-insulin antibodies  which  reflects that  beta  
cell destruction  is due  to  autoimmune process.  The rate of  beta cell  destruction  
is rapid  in infants  and children  and  slower in adults. They have  low or   
undetectable levels of insulin   and  plasma C peptide 
1
. 
Type 2  diabetes  is  the  most  common  form of  diabetes.  It  is  characterized  by  
disorders of insulin action or insulin secretion or both. Patients with type 2 diabetes 
1 
usually have insulin  resistance  rather than absolute insulin deficiency.  This form  
of  diabetes is associated with  progressive  beta cell  failure  and  frequently  goes  
undiagnosed  for many years because the hyperglycemia develops gradually and in  
the earlier stages is not severe enough to produce the classic symptoms of diabetes. 
Both type 1 and type 2 patients are at increased risk of  developing  macrovascular  
and  micro vascular complications. Macro vascular complications such as coronary  
artery disease,  cerebro vascular accidents and  peripheral vascular disease are  not  
directly linked to  the level of  hyperglycemia  but  micro vascular complications  
like  retinopathy,  neuropathy  and  nephropathy  due to  micro angiopathy  have  
been  directly  linked  to  glycemic  control 
2 
. 
Type 1 diabetes is prominent as a disease of child hood, reaching a peak incidence  
around the time of puberty, but can present at any age.The highest rates of type1  
diabetes in the world are seen in Finland and North European countries 
3
. WHO in  
1995 estimated that there 19.4 million people with type 1 diabetes and that the                                
2 
number will rise to 57.2 million by 2025. 
The  development  of  type 2  diabetes  are  influenced  by  attained  age. The 
 Prevalence  of  type  2 diabetes  increases  as  the age  advances . 
 A study  conducted in  monozygotic  and  dizygotic twins  show  that  more 
 frequent  concordance  for diabetes among  monozygotic than dizygotic twins, 
 favours  a  greater role of genetic factors 
1
. 
 The world wide  prevalence of diabetes  has  risen  dramatically over the past  two 
 decades from an estimated 30 million cases in 1985 to 177 million in 2000. Based  
 on current trends, more than  360 million  individuals will  have  diabetes  by  year 
 2030.Although , the  prevalence  of  both  type 1 and type 2  diabetes is  increasing  
worldwide, the  prevalence  of  type 2 diabetes is  rising  much  more rapidly  
because  of  increasing  obesity  and  reduced  activity levels  as countries  are  
becoming  industrialized. Among  microvascular complications, diabetics  have   
20-25 times greater risk of   blindness  as  compared  to  the  general population. 
3 
Diabetic retinopathy is well characterized  by sight  threatening  chronic   
microvascular complication that  eventually affects all patients with diabetes  
mellitus. Diabetic retinopathy refers  to the retinal changes  which is  common   
after the disease  has  lasted approximately10 years. It usually occur in patients  
after the age of 20 years. It affects young or old  according to their  diabetic age  
and  does not  depend  on the actual age of the patient. Duration of diabetes more  
than 10years, poor  glycemic control, heredity, associated hypertension  and   
pregnancy  predisposes the  occurence of diabetic retinopathy 
4 
.  
Electrophysiological tests play an important role in the examination of visual  
system and gives us information about the physiology of  anatomical pathway with  
much less spatial or localizing information.Visual evoked potentials are evoked  
potentials in response to visual stimuli. In this technique, a visual stimulus is given  
to the  subject and  the net  potential  changes taking place in the visual cortex in  
response to stimulus are recorded from the surface electrodes placed over the scalp.  
4 
It is well  acknowledged that VEPs  are very  useful  for  investigating   the   
physiology  and  pathophysiology  of  the human  visual system including visual  
pathways and visual cortex. They can be used  effectively to study  both normal  
and abnormal visual functions  in  the  field of research. 
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 AIMS AND OBJECTIVES 
 To study the VEP responses in type 1, type 2 diabetic patients  and 
controls. 
  Comparing  the  VEP responses  in type 1 and type 2 diabetic 
individuals. 
 To assess the correlation between the duration of diabetes and  wave 
patterns of VEP in type 1 and type 2 diabetics. 
 To evaluate  the  association  between the glycemic control of diabetes 
and wave forms of  VEP in type 1 and type 2 diabetics. 
 Comparing VEP responses in relation to glycemic control and 
duration of diabetes in type 1 and type 2 diabetes. 
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Diabetes is a disease known from ancient times. It is a condition that is extremely 
serious from both clinical and public health stand points. In 1674,Thomas willis, a 
physician and anatomist discovered that the urine of diabetic individuals was 
sweet. This was actually a rediscovery from an ancient Hindu document by 
“Sushruta” in India in about 4th century BC  who had described the diabetic 
syndrome as characterized by honeyed urine. 
 Later in 1776, England physician, Mathew Dobson demonstrated the excretion of 
sugar in urine in diabetics and he noted the residue of  a crystalline material  which 
had the appearance and taste of brown sugar. 
 In 1797, “John Rolto” a surgeon general of Royal artillery first applied the 
discovery of  glycosuria  to the quantitative metabolic  study of diabetes. 
 Later in 1889, “Joseph Von Herring” and “Oscar Minkowski” discovered the role 
of pancreas in diabetes, which made a turning point in the history. “Sir Edward 
Albert Sharpey – Schafer” found that individuals with diabetes were deficient in 
single chemical produced by islets of Langerhans in pancreas and proposed the 
name  “Insulin” from the Latin word “Insula” meaning  “Island”. 
 In 1921 , “Frederick Banting” and “Charle Best” demonstrated the first successful 
insulin preparation for the treatment of diabetes. 
7 
Diabetes is not a single disease entity but rather a group of metabolic disorders 
sharing a common underlying feature of hyperglycemia. Hyperglycemia in 
diabetes results from absolute insulin deficiency,  impaired release of insulin by the 
pancreatic beta cells, inadequate or defective insulin post receptor regulation or the 
production of inactive insulin that is destroyed before it can carry out its action. 
Diabetes may present with characteristic symptoms such as thirst, polyuria, 
blurring of vision, weight loss and polyphagia  and in its most severe form with 
ketoacidosis  or Non ketotic hyper osmolar coma which in the absence of effective 
treatment leads to stupor, coma  and death . 
 
 
 
 
 
 
 
8 
CLASSIFICATION OF DIABETES 
1
 
* Type  1 diabetes  
    Beta cell destruction, usually leading to absolute insulin deficiency. 
 Auto immune  
 Idiopathic  
* Type 2 diabetes  
    May range from predominantly insulin resistance with relative insulin deficiency        
     to a predominantly secretory defect with or without insulin resistance.    
* Other specific types  
  Genetic defects of  beta cell function  
  Genetic defects in insulin action  
  Diseases of the exocrine pancreas 
   Endocrinopathies  
   Drug or  Chemical –induced 
   Infections 
   Gestational diabetes 
9 
Pathophysiology of type 1 diabetes 
 It is sub classified into type 1A and type 1B. 
Type 1A is an autoimmune disease characterized by the pancreatic beta cell 
destruction  and  an  absolute deficiency of insulin. These type of patients have anti 
glutamic acid decorboxylase (GAD ) auto antibodies,  islets cell antibodies (ICA ) 
and decreased C-peptide level in their serum. In the presence of these auto 
antibodies, the patients can be diagnosed earlier before they progress to overt 
diabetes. 
In type 1A,  there is strong association with specific haplotypes or alleles at the  
DQ-A and DQ-B loci of the human leucocyte antigen.It is more likely to be 
associated with other autoimmune disorders such as Graves disease, Hashimoto‟s 
thyroiditis, Addison‟s disease, Coeliac disease, Vitiligo and Pernicious anemia. 
Viral infections such as Mumps, Congenital Rubella, Measles, Chicken pox, 
Coxackie virus and Echo virus in the new born are at high risk to develop 
autoimmunity. 
Type 1B (Idiopathic ) diabetes is a form of diabetes with severe insulin deficiency 
without evidence of beta cell auto immunity. It is a more common form of diabetes 
in a childhood and it is characterized by the low insulin and C-peptide levels and  
10 
such patients are more prone to develop  ketoacidosis 
1
.                    
Patho physiology of type 2 diabetes:   
It is caused by a combination of peripheral resistance to insulin action and an 
inadequate  secretory response by  the pancreatic beta cells. 
Insulin resistance develops from the complex interplay of genes, obesity, 
environmental,  nutritional, hormonal factors  and advancing age. 
 
Genetic      Environmental         Obesity    Nutritional and Hormonal           Age 
 
                           
                                  INSULIN  RESISTANCE 
Beta cell dysfunction : 
                                 The beta cell defect in type 2 diabetes is the loss of first phase  
(0-10 minutes after glucose intake ) of glucose induced insulin secretion. This 
observation was first made in the late 1960s, when persons with type 2 diabetes  
11 
were noted to have a  delayed  insulin response to intravenous glucose, and later 
was recognized as loss of the first phase. The second  phase is also impaired  but  
to a lesser degree. There are many  biochemical and molecular mechanisms have 
been proposed for the induction of  beta cell dysfunction by hyperglycemia which 
includes excess glycogen storage, impaired glucose transport in to the  beta cell, 
impaired activity of key signaling pathways such as the glycerol phosphate shuttle 
or  pyruvate carboxylase,  defective ATP - sensitive  channel activity,  altered         
Na 
+
- K 
+
- ATPase  activity coupled with  reduced myoinositol  uptake and loss of 
beta cell differentiation
 1
 . 
 The diagnostic criteria of diabetes: The diagnosis of diabetes is established by 
monitoring the elevation of  blood  glucose by any one of the three criteria
 5
. 
1) A random glucose concentration greater than  200 mg /dl. 
2) A fasting glucose concentration greater than 126 mg /dl on more than one 
occasion . 
3) An abnormal oral glucose tolerance test in which glucose concentration is  
more  than 200 mg /dl, 2hrs after intake of 75 gms of oral glucose after 
overnight fasting. 
12 
Diagnostic criteria for diabetes mellitus  
Diabetes mellitus  Capillary whole blood     
           (mg/dl ) 
 Venous plasma  (mg /dl ) 
Fasting             ≥ 110             ≥  126  
2 hours post glucose             ≥ 200             ≥   200 
 
Oral glucose tolerance test : 
 
 
Capillary blood (mg/dl) Venous blood(mg /dl )  
Diabetes mellitus 
  
Fasting  
       ≥ 140          ≥ 140 
2hrs after glucose load         ≥ 200     ≥ 200 
Impaired  Glucose 
tolerance 
  
 Fasting                                < 140    < 140 
 2hrs after glucose load    160 - 200      140 - 200 
 
13 
  
 
 
 
  
Complications of Diabetes : 
The complications of diabetes are mainly related to persistent hyperglycemia. 
The microvascular complications in diabetes includes retinopathy, neuropathy, 
nephropathy and the mechanisms involved in microvascular complications are 
oxidative stress, glycation and activation of protein kinase C in capillary 
endothelial cells  and  pericytes. 
In the retina, the structural changes such as thickening of capillary basement 
membrane, increased vessel permeability, capillary micro aneurysm and loss of 
retinal pericytes, leads to the development of diabetic retinopathy. 
In the renal vasculature,  thickening  of  the  glomerular  basement membrane 
and  expansion of the mesangium  are the dominant morphologic features in 
diabetic nephropathy
 
 . 
In the nerves, the hyperglycemia induced intrinsic changes in the neurons and 
the ischemia induced neural damage by decreased neurovascular blood flow are 
multifactorial causes of  diabetic neuropathy. 
Macrovascular complications  such as coronary artery disease,cerebrovascular 
accidents and peripheral vascular disease are due to the atherosclerotic changes  
14 
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in the vessel wall. 
The ocular complications of diabetes are diabetic retinopathy, mononeuropathy 
of extra occular muscle, recurrent erosions in the cornea, neovascular glaucoma 
and diabetic cataract. Among these complications, diabetic retinopathy is more 
common 
6
. 
Diabetic retinopathy : 
Diabetic retinopathy is a well characterized sight threatening chronic 
microvascular complication that eventually affects all patients with diabetes 
mellitus . Almost all patients with type 1 diabetes develop a retinopathy in 
about 15 years. In type 2 diabetes, the risk of retinopathy increases with 
duration and control of diabetes, associated hypertension, dyslipidemia, 
pregnancy, renal disease and  smoking 
4
. 
In patients diagnosed before the age of 30 years, the incidence of retinopathy 
after 10 years is 50 % and after 30 years is 90 % . Diabetic retinopathy rarely 
develops within 5 years of onset of diabetes. 
Eva Kohner’s classification of Diabetic retinopathy 4 
1) Back ground retinopathy 
15 
PRE-PROLIFERATIVE DIABETIC RETINOPATHY 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROLIFERATIVE DIABETIC RETINOPATHY 
 
 
 
2) Non proliferative diabetic retinopathy (pre proliferative DR ) 
3) Proliferative diabetic retinopathy 
In Background retinopathy, the characteristic changes are capillary micro 
aneurysm, dot and blot hemorrhages, hard exudates and  maculopathy. Macular 
oedema is the commonest  cause of diminution of vision . 
In pre proliferative diabetic retinopathy, multiple cotton wool or soft exudates 
are present, due to retinal ischemia as a result of capillary occlusion in the  
nerve fibre layer. 
In proliferative diabetic retinopathy, the characteristic changes are 
neovascularization, vitreous hemorrhages  and retinal detachment. 
The 5 year risk of severe visual loss from proliferative DR is less than 2% and 
moderate visual loss from macular edema is around 12 % . 
Pathophysiology of Diabetic retinopathy : 
Pathogenetic mechanism for the development and progression of DR 
    Biochemical changes  
     Increase protein kinase C activity,  non enzymatic glycosylation , aldose    
16 
  
 
 
 
 
 
 
 reductase activity, vasoactive substances release ( Endothelin, Prostanoids,     
     Histamine, NO) , increased free radical damage, growth factor release.  
    Functional changes :  
    Altered blood flow and oxygenation, increase in the capillary permeability. 
    Anatomical changes : 
    Mural cell loss, Endothelial proliferation, Capillary closure, Micro aneurysm     
   formation and neovascularisation
7
. 
Electrophysiological tests  play an important role  in the  examination  of  visual 
system. They are  used  mainly  to  confirm the clinically suspected  neurological 
or ophthalmological diseases like Multiple sclerosis or  Retinitis pigmentosa.They 
also play an important role in the evaluation of  unexplained  visual loss  without  
physical abnormalities, assessing the function of retina in cases of opacities in the 
media, quantification of visual abnormalities like uveitis and  assessing  the retinal 
and optic nerve function following trauma . 
Evoked responses measures the electrophysiological responses of the nervous 
system to a variety of stimuli .The commonly encountered responses are visual  
17 
evoked responses (VEP ),  short -latency  somato sensory evoked responses 
(SSEP) and short latency brain stem auditory evoked responses (BAER ,BAEP). 
The clinical use of  evoked potentials (EPs) has changed over time.  Progressive 
advances in imaging technology have limited the frequency of evoked response 
studies in clinical practice.Evoked potentials explains the functionality of certain 
anatomical pathways of the nervous system. 
VISUAL EVOKED POTENTIAL: 
VEPs are electrical potential differences recorded from scalp in response to visual 
stimuli. Normal cortical responses are recorded if the entire visual system is intact 
and disturbances anywhere in the visual system can produce abnormal VEPs , there 
fore the localizing value of VEP is limited . It is a non invasive  electrodiagnostic 
technique.  They can be used effectively to study both normal and abnormal visual 
functions in the field of research. They have an excellent temporal resolution in the 
range of milliseconds thus permitting the study of dynamic changes occurring in 
the nervous system 
8
.  
History: 
In 1934, Adrian and Matthew noticed potential changes of the occipital EEG can  
18 
be observed under stimulation of light.  
Ciganek developed the first nomenclature for occipital EEG components in 1961. 
During that same year, Hirsch and colleagues recorded a VEP on the occipital lobe 
(externally and internally), and they discovered amplitudes recorded along the 
calcarine fissure were the largest. 
 In 1965, Spehlmann used a checkerboard stimulation to describe human VEPs. An 
attempt to localize structures in the primary visual pathway was completed by 
Szikla and colleagues.  
Halliday and colleagues completed the first clinical investigations using VEP by 
recording delayed VEPs in a patient with retrobulbar neuritis in 1972. A wide 
variety of extensive research to improve procedures and theories has been 
conducted from the 1970‟s to today. 
Methods of VEP: 
The commonly used techniques for performing  VEP are  pattern reversal VEP 
(PR-VEP), pattern onset/offset  and  flash VEP (FVEP). 
In pattern reversal VEP the subject is asked to focus on a checker board pattern of  
19 
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alternating black and white squares displayed on a monitor in which the colors 
interchange at fixed frequency. In pattern onset/offset VEP the checker board 
pattern is exchanged with a diffuse grey background with no change in luminance. 
FVEP is a technique in which repeated flashes of light of fixed luminance, 
frequency and color are given as stimuli, using xenon flash tube. 
Pattern reversal is the prefered stimulus for most clinical purposes. It shows less 
variations in waveforms and their timing than other techniques. Pattern onset/offset 
stimulus is best suited for detection of malingering and for use in patient with 
nystagmus. FVEPs are used only in cases of poor optics, poor cooperation and 
poor vision 
Anatomical basis of visual evoked potential  
The optic nerve joins the retina with the brain.  The receptor or end organ through 
which visual impulses are mediated are rods and cones of retina.They are 
stimulated by light impulses and synapse with inner nuclear or bipolar layers , the 
cells of which in turn synapse with ganglion cell layer . The axons of the ganglion 
cells form the optic nerve, which  extends from the retina to optic chiasma and is 
about 5 cm long, of which 3.5 cm is in the orbit and 1.5 cm in the optic foramen  
20 
and  within  the  skull. Approximately 1 million  fibers  of  optic  nerve  are 
unmyelinated in the retina and optic nerve head but these become myelinated as 
these pass through lamina cribrosa.  The two optic nerves unite at optic chiasma. 
The fibers from the temporal half of the retina are  situated in the temporal half of 
the nerve and pass through the chiasma without crossing and terminate at the 
ipsilateral cortex, but the fibers from the nasal half of the retina decussate at 
chiasma  and terminate at the contralateral cortex. The optic tract starts from the 
optic chiasma  and terminates in the dorsal lateral geniculated nucleus located at 
the dorsal end of thalamus within the lateral geniculate bodies. Fibers carrying 
impulses from the upper portion of the retina terminate in the ventromedial 
segment and those from the lower portion in ventro lateral segment of LGB. The 
ipsilateral temporal fibers terminate in layers 2, 3 and 5 whereas the contralateral 
fibers terminate in layers 1, 4 and 6. Approximately  50 % retinal ganglion cells 
decussate at the optic chiasm to innervate the contralateral lateral geniculate 
nucleus.This results in the monocular VEPs having similar amplitudes at the 
cortex. Neurons originating from LGB form optic radiations       
(Geniculocalcarine fibers )  pass posteriorly to terminate in the striate cortex (area 
17 ). The macular fibers occupy the larger portion of occipital lobe at the pole in a 
wedge shaped area. The upper half of retinal fibers relay superior and the lower  
21 
half inferior to the calcarine fissure. 
The P100 wave form of VEP is generated in the striate and peristriate occipital 
cortex is due to the activation of primary cortex on giving pattern or flash 
stimulation. There is increased metabolism in the primary visual area and as well 
as in the visual association area ( area 18 and 19 ). The regional cerebral blood 
flow increases with stimulation rate up to 8 Hz and gradually declines there after. 
VEP is primarily a reflection of activity originating in the central 3 - 6 degree of 
the visual field, which is relayed to the surface of occipital lobe. 
Cells in the striate cortex are arranged retinotopically as in the LGN, thus, two 
cells located next to one another in the cortex process information from areas of 
visual field located next to one another. There is a significant divergence of 
information from the macula to the cortex. Approximately half of the striate cortex 
is devoted to processing information from central 10 degrees of visual field.  Most 
of the cortical cells are devoted to the macula, therefore VEP is principally a 
macular response
 9 
. 
VEP is a sensitive indicator of optic nerve function. It is an evoked electro 
physiological signal that is recorded at the scalp in response to visual stimuli. The 
22 
responses are smaller than ERG responses, typically measuring 5-10 micro volts in 
amplitude. Averaging of the recorded signal over a given time period after repeated 
stimulation can help in extraction of VEP from the  background  EEG activity. 
The visual system processes information along with multiple parallel channels. The 
separation of visual information starts at the neuronal circuitry of the retina where 
particular features such as color, contrast, luminance and other parameters of the 
stimulus are extracted and processed. It has been suggested that seven parallel 
channels of ganglion cells process visual information in the primate retina. These 
retinal neurons send central projections to the LGB. 
Dorsal lateral geniculate nucleus  is divided into  
1) Magno cellular layer 
2) Parvo cellular layer 
Layer I and II are called magnocellular layers because they contain large neurons. 
They receive the input from large type of Y retinal ganglion cells. This provides a 
rapidly conducting pathway to the visual cortex 
10 
. 
The parvocellular layers ( layers III, IV, V, VI ) contain large number of small to 
medium sized neurons, these neurons receive input from the type X retinal 
23 
ganglion cells that transmit  color and generate  point – point spatial information 
but only at a moderate velocity of conduction. So the magnosystem is involved 
primarily with motion analysis. The parvocellular system shows a preference for 
high spatial frequency stimuli. 
Visual pathways emphasizes the extent to which the neocortex is involved in 
parallel visual processing. There are two pragmatic principles that can be derived 
from the above data.  
1) Visual stimuli not only activate the occipital lobes but also involve large 
areas of temporal and parietal lobes.  
2) Different structures of the retinal and visual pathways can be preferentially 
activated by changing the characteristic of visual stimuli. 
The first principle indicates that VEPs can be recorded from a large region of 
the scalp, essentially from the vertex  to the  inion.            . 
BASIC TECHNOLOGY: 
National federation of clinical neurophysiology (IFCN) described the standards 
of basic technology for recording VEPs 
10
. The principle of recording VEP are 
simple. A visual stimulus is presented to the subject for a selected number of  
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times and the cerebral responses are amplified, averaged by a computer and 
displayed on  an oscilloscope screen or printed out on paper. For neurological 
purposes, VEPs are generally elicited by monocular stimulation of each eye 
while the other is covered with a patch. Visual stimuli can be either patterned 
stimuli  or  unpatterned stimuli. Unpatterned stimuli most frequently consists of 
stroboscopic flashes.  Patterned stimuli consists of specific pattern such as 
checks or bars on which the subject is required to fixate. The two most 
frequently used patterns are checks and gratings. The pattern should be 
achromatic (black and white). The size of the individual checks should be 
expressed in terms of visual angle. 
Visual angle β is expressed as β = tan-1 (W /2D ) X 120  where β is visual angle   
in minutes of arc; W is the width of checks in millimeters and distance of 
pattern from the corneal surface in millimeters. The measurement in cycles per 
degree define the spatial frequency of stimulus. Measurements of the visual 
cycle in minutes of arc can be converted to cycles per degree by the formula    
C / degree = 30 /W . 
The most frequent method of presentation of the stimulus is by reversal of 
checkerboard pattern. The black checks become white and vice versa so that  
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there is no change in the total luminance (Iso luminance) of the pattern. 
Isoluminance is important in preventing light scatter in the retina. The VEP is 
affected by the stimulus intensity. Intensity of stimulus is defined by luminance. 
The mean luminance of the field of stimulation is expressed by  the formula   
                                                 Lmax + Lmin /2 
    Where L max  indicates  the maximum and  L min  indicates   minimum  
   luminance of the field. A desirable mean field luminance is at or above              
  100cd/m
2
. Another important parameter that may modify VEP is contrast.     
Contrast is defined as difference between bright and dark portion of a pattern. It is 
expressed by the formula  C={(Lmax – Lmin)/(Lmax +Lmin)}x 100. 
The IFCN recommends that a minimum of three stimuli be used for testing and 
suggests the following parameters.  
1) Pattern stimuli consisting of either checks or gratings 
2) Size of the pattern elements 14‟-16‟, 28‟-32‟, 56-64‟ 
3) Full field size at least 8 degrees (1degree=60minutes) 
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4) Contrast between 50 – 80 percent  
5) Rate of presentation 1 Hz (producing a reversal every 500 m sec ) 
6) Mean luminance of center field at least 100cd/m2 
7) Background luminance under photopic condition at least 30 -50 c d/m2 
8) The distance between subject eye and screen should 70-100cm 
The IFCN suggests a two channel montage, Oz – FPz and Oz-A1- A2 (linked 
ears), with the ground  placed at CZ for recording VEPs. The band pass low cut 
filters are set at 1-3Hz and high cut filters at 100 - 300 Hz, on reducing the high 
cut filters the P100 latency decreases. So the filter setting should be kept 
constant. The subject  fixates on the  center  of the  pattern  during  stimulation. 
The responses are recorded at least twice to ensue  their replicabity. 
NORMATIVE DATA : 
VEPs  to a pattern-reversing checker board (the most frequently used stimulus 
in clinical laboratories) consists of a set of sequential wave forms. For recording 
VEP, standard disc EEG electrodes are used. The skin is prepared by abrading 
and degreasing.The recording electrode is placed at Oz using conducting jelly  
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or electrode paste asper 10-20international system of  EEG electrode placement. 
The reference electrode is placed at FPz or 12 cm above the nasion. The ground 
electrode is placed at vertex. The electrode impedance should be kept below 5 k 
Ω. These electrode positions are used to ensure reproducible electrode 
placement in serial studies and do not represent respective cortical areas. An 
amplification ranging between 20,000 and 100,000 is used to record pattern 
shift visual evoked potentials ( PSVEP ). Sweep duration should range between 
250 and 500 miliseconds. A short sweep duration alters the P100 wave forms, 
generally 100 epochs are averaged. The averaging some time may have to be 
increased to 200 –500 epochs to ensure a clear potential. The mono ocular full 
field stimulations is used always, so that the test is most sensitive to lesions of 
optic nerve anterior to chiasma. The VEP wave form is the sum of many wave 
forms generated simultaneously by various areas of retinotopically organized 
occipital cortex. The negative wave form is denoted as “N” and positive 
deflection as “P” which is followed by approximate latency in  milli seconds. 
The commonly used wave forms are N70, P100 and N135. The primary basis for 
interpretation of VEP is measurement of latency of P100 component (the normal 
P wave latency is 100 milliseconds in normal persons) after stimulation 
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POSITION OF RECORDING ELECTRODES 
 
Oz - active, Fz- reference electrode, Cz- ground electrode 
(The subscript z indicates a midline position) 
 
NORMAL TRACING OF VEP WAVE FORMS 
 
of  each eye separately. After the absolute P 100 latency for each eye is 
measured, the inter eye P100 latency difference is determined . Comparison of 
these values with normative laboratory data will indicate normal or abnormal 
nature of response. Unilateral prolongation of P100 latency after full field  mono 
ocular stimulation  implies an abnormality anterior to the optic chiasma on that 
side. Bilateral lesions either anterior or posterior to the optic chiasma or a 
chiasmal lesion will cause bilateral delay of P100 latency. 
 Normal values of visual evoked potential 
9 
       Parametes  P100                    Mean  ± SD  
          Latency (ms)                        96.9± 3.6 
          R-L (ms )                       1.5 ± 0.5 
          Amplitude (μv)                        7.8 ± 1.9  
           Duration                          55.9 ± 7.7 
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Variables influencing VEP 
9 
Age: 
Age influences the latency of P100 at a rate of 2.5 ms / decade after 5
th
 decade. This 
has been attributed to age-related changes in both retina and the rostral part of 
visual system. The changes which include ganglion cell loss, demyelination, 
axonal swelling, nerve fiber loss are due to changes in the neuro transmitter 
function and increased synaptic delay in senescence. The amplitude  of VEP 
remains stable in adult life.  
Gender :   The P100 latency is longer in adult males compared to females. This is 
due to larger head size and lower core body temperature in males. In the age group 
below 19 years,   P100 latency does not vary with sex although a longer latency has 
been reported in girls. The P100 amplitude is greater in females compared to males, 
cause is unknown probably due to hormonal influences have been suggested. 
Eye dominance:  
                    P100 wave obtained by stimulating the dominant eye is shorter and 
amplitude greater compared to the non dominant eye. This is due to neuroanatomic 
asymmetries of human striate cortex. 
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Eye movement:    Eye movement reduces the amplitude of P100 but its latency is 
not affected. The patients with nystagmus having a normal visual pathway also 
have a normal   P100 latency. 
Visual acuity: 
                 P100 latency remains normal in spite of pronounced diminution of visual 
acuity. The latency of  P100 is reported to be normal with visual acuity as low as 
20/120;  however, the amplitude decreases with further reduction of visual acuity. 
Drugs: 
          Drugs  producing  pupillary constriction such as pilocarpine can increase     
P100 latency, which is attributed to decreased area of retinal illumination. The 
mydriatics result in an opposite effect. 
Reproducibility and Variability: 
                   During mental activity such as problem solving, the P100 latency has 
been reported to decrease and the amplitude increase. An unmotivated patient may 
alter the  P100 latency or amplitude by closing the eye, gazing off the screen, 
converging in front of target or even his nose. Although the VEP wave forms are 
reproducible, they have an inherent intra individual variability. 
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Abnormal visual evoked potentials 
Abnormalities of VEPs have been described in many disorders of optic nerve, 
chiasma and retro chiasmatic visual pathways. The VEP can be considered 
abnormal when the latency of  P100 wave is outside the 95-99 percentile boundaries 
established for normals. Delay or absence of N70 peak is more difficult to evaluate, 
because this component is variable in different subjects. The most frequent 
abnormality is characterized by a normal amplitude but a prolonged latency of N70 
and  P100. The intereye latency difference is useful to locate the side of the lesion , 
the latency difference between the two eyes greater than 10 ms is indicative of 
pathology on that side with longer latency. 
The commonest cause of prolonged of P100 latency is demyelination in the optic 
pathways where the amplitude of the P100 remains normal. The ischemic optic 
neuropathy leading to axonal loss produces the normal  P100 latency and decreased 
amplitude. Optic nerve compression produces segmental demyelination and axonal 
loss resulting in both latency and amplitude abnormalities in VEP. Diabetic 
retinopathies, maculopathies, retinal infarcts and scars are associated with 
abnormal VEPs 
9
. 
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Causes of abnormal visual evoked potentials 
8 
Ocular disease: 
Major refractory errors,  lens  and media opacities, Glaucoma, and Retinopathies. 
Compressive lesions:  Extrinsic tumors, Optic nerve tumors. 
 Non compressive lesions : 
 Demyelinating disease,  Ischemic optic neuritis, Nutritional and toxic amblyopias. 
Diffuse central nervous system disease:  Adrenoleukodystrophy,  Spinocerebellar        
degenerations and Parkinson‟s disease. 
Studies of visual evoked potential in diabetes mellitus 
Pan CH , Chen SS conducted the study of pattern shift visual evoked potentials 
on 46 cases of NIDDM and 13 cases of IDDM showed the prolongation of all 
peak latencies 
11 
. 
Fierro B et al studied in a group of 35 patients with 10 or  more  years of 
duration of diabetes, the P100 latencies of VEP were found significantly 
prolonged in 10 (28%) patients 
12
.  
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Parisi V et al conducted the study of VEP after photo stress in insulin dependent 
diabetic patients with or without retinopathy, the study showed a prolonged  
P100 latency which was significantly higher in IDDP and IDDP-WR than in 
control groups 
13
 . 
Dolu H et al conducted the study in 51 patients with type 2 DM showed 
prolongation  of P100  latency of VEP  related to duration of disease 
14. 
Karlika D et al studied the use of visual evoked potential in 45 type 1 DM 
patients to detect a pre diabetic form of diabetic retinopathy.The study showed 
the P100 latency values increases progressively as the year passes. They 
concluded that  increase in VEP latency are a direct sign of retinal ganglion cell 
damage 
15
. 
In a study on 35 diabetics and controls by puvendran k, Devathasan G  and   
wong pk, it was found that latency was increased  by more than one standard 
deviation  in  13 diabetics (81%)  and  more  than  three standard  deviation in 
10 diabetics (62.5%) and often associated with marked reduction in amplitude. 
They found that extent of optic nerve involvement in 16 diabetics without 
development of  retinopathy  and  other ocular diseases 
16
.  
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Dr Sami ulus, Turkey studied the VEP and its relation with HbA1c in children 
with IDDM. It was found that VEP latencies of the diabetic children in both 
eyes were significantly prolonged when compared with control group. There 
was a positive correlation of prolongation of  P100 latency with HbA1c 
17
. 
The study was conducted by  Pozzessere G et al in  both type 1 and type 2 
diabetic patients. It was found that VEP latencies were  significantly  prolonged  
and these prolongation  occurs only a few years after clinical diagnosis and 
before the appearance of overt complications and  seem to be correlated with 
metabolic control  status 
18
. 
In other study conducted by Ponte F, Giuffre G, Anastasi M, Lauricella M , in 
62 type 1 diabetics showed the delayed latencies of VEP on pattern reversal 
stimulation . A positive correlation was found between the VEPs latencies and 
duration of diabetes 
19
. 
A longitudinal study in NIDDM conducted by Moreo G, Mariani E, 
Pizzamiglio G, Colucci GB to assess the possible progression of neurological 
abnormalities overtime and VEP in predicting the diabetes related optic 
pathway disease. It was found that the peak P100 wave latencies were  
35 
significantly delayed in diabetics compared with the control subjects and the 
VEP alteration were stable over time and correlated positively with metabolic 
control 
20
.  
Collier A, Mitchel JD and  Clarke BF  conducted the study on 22 insulin 
dependent diabetics aged  20-35 years of whom  5 did not  have retinopathy, 11 
had back ground retinopathy  and 6 had proliferative retinopathy and it was 
found that all patients with proliferative retinopathy showed delayed VEP 
latencies 
21
 . 
Yaltkaya K, Balkan A, Baysal conducted the study to investigate the possible 
effects of the disease on central nervous system by means of pattern shift VEP. 
It was found that in diabetic patients latency prolongation in  P100 and N140 
components were observed and in patients with long standing diabetes mellitus, 
the incidence of VEP abnormalities were found to be high 
22
. 
Comi G studied the abnormalities of central afferent and efferent pathways, by 
evoked potential studies in diabetic patients and it was found that VEP latencies 
were abnormal in central nervous system disease and peripheral neuropathy but 
latencies were  abnormal in  central nervous system disease  and  peripheral 
36 
     neuropathy but VEP can be abnormal even in patients without retinopathy 
23
. 
Verotti A et al conducted the VEP study in young persons with diabetes in basal 
condition and after photo stress in 30 newly diagnosed patients with diabetes 
and showed that the  P100 latency was significantly delayed in patients with 
diabetes compared with control group and  measurements were repeated after   
6 months, when all diabetes had achieved good metabolic control, a complete 
normalization of parameters was observed suggest that early functional 
abnormalities of the optic nerve can be detected at the onset of  diabetes and the 
glycemic control reverses these abnormalities 
24
 . 
Tamas T.Varkonyi et al conducted the study in type 1 diabetes and found that 
VEP measurements were impaired even at an early stage of the pathogenetic 
process 
25
. 
Michel Algan et al conducted the VEP test in 50 adult type 1 and 19 type 2 
diabetics and in 54 controls. P100 wave latency was significantly longer in 
diabetic patients (P<0.001) found that there was no correlation between  P100 
latency and  type or duration of diabetes or quality of metabolic control 
26 
. 
Ziegler Oet al conducted the study of VEP in poorly controlled diabetic patients 
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after short-term metabolic control, to determine whether short term strict control of 
blood glucose can improve abnormal VEP in 12 poorly controlled diabetic patients 
before and after at least 3 days of near normoglycemia obtained by continuous 
insulin infusion. The result showed that  P100 latencies were longer in diabetic than 
in control subjects (P< 0.01) and after 3 days of blood glucose control, the mean 
P100 latencies were significantly shorter but were still significantly longer than 
control values. There was no correlation between fall in blood glucose and 
improvement in VEP 
27
. 
Eliya et al did a study of color VEP in children with type 1 diabetes with relation to 
metabolic control. The study showed that VEP latencies were not associated 
significantly with HbA1c. However, pubertal children with type1DM   had  
delayed VEP  latencies when compared with the pre pubertal children with type 1 
DM 
28 
.  
Deepika chopra,  Mridu gupta,  Manchan K.C, Ram sarup sharma , Rajender sing 
sidhu conducted a study in patients of type 2 diabetics . The result showed that 
significantly prolonged N70, P100 latencies in diabetic patients and also significant 
correlation between the delay in P100 latency and the duration of disease 
29 
. 
Vincenzo parisi et al  conducted a study of  VEP in newly  diagnosed  IDDM  
38 
 patients. The results  showed  that VEP P100 latencies  significantly  delayed 
(P<0.01) in diabetics, compared with control subjects 
30
. 
Raman PG, Sodani A, George B conducted a study of VEP changes in 25 diabetic 
patients. The result showed that P100 latencies and amplitude were significantly 
prolonged (P=0.001). A positive correlation was documented between glycemic 
control and prolonged P100 latencies. There was no correlation between presence 
and absence of peripheral neuropathy and delay in P100 latencies 
31
. 
Costache D,  Damianc, Iancau M conducted the VEP recording in 24 diabetic 
patients with retinopathy and it was noticed that delay of P100 wave with inconstant 
presence of  N75 and  N135 waves 
32
. 
Algan et al conducted the VEP testing in 50 adult type 1 and 19 type 2 diabetic 
patients and in 54 controls. The results showed that P100 wave latency was 
significantly longer in diabetic patients (P<0.001) 
33
. 
Cirillio D et al conducted  a study of VEP in 30 IDDM  children and  adolescents. 
The result  showed  that  30% of subjects had  evidence of significant 
abnormalities 
34
. 
Fiona M.E Ewing, Ian J.Deary, Mark W.J.Strachan and Brian M.frier conducted 
39 
the electrophysiological study in diabetic patients and they concluded that good 
evidence exists for abnormalities occurring in P100 response in people with diabetes 
before the development of overt retinopathy ranging from the newly diagnosed 
patients with IDDM to those with diabetes of longer duration 
35
. 
Filiz A frashi et al performed the VEP recording in 20 IDDM patients and 
compared with age matched controls using pattern reversal VEPs. The study  
revealed that mild prolongation of P100 latencies in IDDM patients  compared to 
controls  (99.6 ± 7 ms ) 
36
. 
Radha shenoy et al conducted a VEP study in uncontrolled type 1 & type 2 diabetic 
patients before and after pan retinal laser treatment. The study results showed that 
P100 latency increased before and after treatment. The P100 amplitude was not 
changed before treatment but significant decrease in P100 amplitude after   
treatment 
37
. 
Shinoda kei et al conducted a study in a patient with proliferative diabetic 
retinopathy with development of ischemic optic neuropathy after pars plana 
vitrectomy. On the first post operative day, the patient noticed a defect in visual 
field in the operated eye. VEP in that eye had slightly delayed latency and  
40 
    electroretinography  showed  almost normal response in the operated eye 
38
. 
Uberall M.A, Chr.Renner, Parzinger E, Wenze D perfomed a VEP study in 29 
type 1 diabetic children and adolescent compared with 29 controls. The IDDM 
subjects showed highly significant latency prolongations (P<0.001) for P100, 
N150, P200 and P300 compared with healthy controls 
39
. 
Pioter rajewski et al conducted a VEP study in 90 patients with type 1 & 2 
diabetes. Abnormal VEP were common in patients with clinical signs of 
peripheral neuropathy (P=0.004), insufficient glycemic control (P<0.02), type 2 
diabetes (P= 0.004) and in elderly patients (P < 0.001) 
40
. 
Marta Wysocka - mincewicz et al evaluated the coexistence of abnormalities in 
the peripheral nervous system and  VEP in  children with  type 1 diabetes. 
There was a significant prolongation of P 100 latency (P<0.05) among the 
children with polyneuropathy verses the children without poly neuropathy 
41
. 
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MATERIALS AND METHODS 
STUDY DESIGN: 
This is a combined  cross sectional and  case control study. 
STUDY PLACE AND STUDY PERIOD: 
This study was carried out in the Research laboratory of the Department of 
Physiology, Coimbatore medical college, Coimbatore. The study period extended 
from June 2010 to June 2011. The approval of the Ethical committee was obtained 
prior to the commencement of the study. 
STUDY SUBJECTS: 
A total of 80 subjects were included in the study of which 40 were diabetic patients 
(both type 1 and type 2) and 40 were control groups. They were of 30-70 years of 
age group. All the cases of diabetic mellitus were taken from diabetic clinic of 
Coimbatore Medical College Hospital and the controls were taken from the general 
population. The study subjects of both sexes were divided in to two groups.  
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Group I - 40 controls, age and sex matched healthy individuals. 
Group II – 40 diabetic patients. 
Group II A  - 20 type 1 diabetic patients 
Group II  A1 -  0 - 10 years of duration of diabetes  
Group II A2  - 11 – 20 years of duration of diabetes 
Group II A3 - more than 20 years of duration of diabetes 
Group II A4 - patients with good glycemic control 
Group II A5  - patients with poor glycemic control 
GROUP II B - 20 type 2 diabetic patients 
Group II B1 - 0 – 10 years of duration of diabetes  
Group II B2   - 11 - 20 years of duration of diabetes 
Group II B3 - more than 20 years of duration of diabetes 
Group II B4 - patients with good glycemic control 
Group II B5  -Patients with poor glycemic control 
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INCLUSION CRITERIA: 
Diabetic and normal subjects of both sexes in the age group of 30 – 70 years were 
included. Detailed ophthalmological check up of all patients was done, which 
included visual acuity, recording of ocular tension and fundus examination under 
full mydriasis. 
EXCLUSION CRITERIA: 
Patients having a history of any disorder which could influence the interpretation 
of results such as  
Retinopathy 
Glaucoma  
Cataract  
Hypertension were excluded from the study. 
MATERIALS USED FOR THE STUDY: 
1. NeuroPerfect EMG 2000 system – to collect, analyze, print and store a visual 
evoked potential data. 
2. Autoanalyser – to analyse plasma sugar and HbA1c levels. 
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METHODOLOGY: 
The study was carried out after explaining the procedures in detail and getting 
informed consent from the subjects. The study was approved by the Ethical 
committee of Coimbatore Medical college. The study protocol involved  
1. Recording of a detailed history including history and duration of diabetes, 
history of hypertension, coronary artery disease, glaucoma and cataract from the 
study subjects. 
2. A thorough clinical examination of the study subjects. 
3. Measurement of blood sugar and HbA1c level:  
Blood samples were collected by sterile technique using disposable syringes. 
Fasting samples were collected in the morning after 12 hours of fasting from  40 
diabetics and 40 control subjects. Post prandial blood sugar samples were collected 
2 hours after breakfast. Blood samples were collected from 40 diabetic patients to 
estimate HbA1c level. Fasting and post prandial blood glucose and HbA1c were 
estimated using an autoanalyser. 
Glycated  Hb testing : 
Hemoglobin is normally glycated with glucose to form HbA1c.  This glycation is  
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irreversible and the level of HbA1c present in the blood increases with high blood 
glucose levels. So it provides an index of blood glucose level over the previous 6 
to 12 weeks. Normal value of HbA1c is < 6.5.                                                                                                                                    
Autoanalyser 
Autoanalyser is an open, fully automated, discrete, patient prioritized, random 
access, computerized analyzer. It is intended for in vitro quantitative determination 
of a wide range of analytes in various body fluids. The analyzer operation is very 
user friendly with minimum handling required from the operator. The working unit 
of the analyzer comprises a basic operating unit with an intelligent photometer and 
sophisticated robotics combined with an operating console and a central processing 
unit. The photometer uses a flat field polychromator for measuring the optical 
densities of reaction mixtures. The results thus obtained were tabulated and 
analysed. 
4. Procedure for recording visual evoked potential: 
 Pattern- shift visual evoked potential test was performed in a specially equipped   
electro diagnostic procedure room (darkened, sound attenuated room). The patients 
were explained about the test and should avoid hair spray or oil before the test. The  
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PHOTOGRAPHS SHOWING THE METHOD OF RECORDING VEP 
 
 
 
 
patient were seated comfortably one meter away from the pattern – shift screen. 
Subjects were placed in front of a black and white checker board pattern displayed 
on a video monitor. Standard silver chloride electrodes of 1cm diameter were used 
for recording. International 10 – 20 system nomenclature was used for recording 
electrode position. The electrodes were applied to the scalp using conduction jelly 
after thoroughly cleaning the area. Recording electrode was placed at Oz position, 
reference electrode was placed at Fz and the ground electrode placed at M1position 
using conducting jelly. Subjects were given 5 minutes to get acquainted with 
laboratory environment before carrying out the actual procedure. The pattern – 
shift screen checks changes alternatively black/white to white/ black at a rate of 
approximately twice per second. Every time the pattern changes, patient‟s visual 
system generates an electrical response which was detected and recorded by 
surface electrodes. The patient was asked to focus his gaze on to the center of the 
screen. Each eye was tested separately, while the other eye was being covered with 
an opaque patch. The participants were watched by the examiner for any eye 
movements or attention lapse during the procedure. This has been considered as 
standard technique for the present study.     
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RESULTS 
 
 
 
 
 
 
 
 
 
RESULTS 
The present study was conducted in the Department of physiology, Coimbatore 
medical college, Coimbatore. 40 diabetic individuals and 40 controls were selected 
for the study. One way ANOVA & Student „t‟ test were used to assess the 
statistical significance. All data is expressed as mean ± S.D.The mean value, 
standard deviation of VEP parameters of right and left eye in the Groups I, IIA and 
IIB  are shown in the (Table 1-4)  
The data revealed that: 
The mean value of the P100 latency was significantly delayed in  Group II A    and 
Group II B patients as compared to that in Group I subjects. There was no 
significant prolongation of N75  and N145  latencies in Group II A  and Group II B  
patients as compared to Group I subjects. (Table – 1/ Fig:1,2) 
The mean value of the N75-P100 amplitude was not significantly decreased in Group 
II A  and Group II B  patients as compared to Group I subjects. (Table - 1/ Fig:1,2) 
Comparison of VEP responses was done between Group II A  and Group II B. There 
was no statitically significant difference found between these two groups. 
(Table - 2 / Fig: 3,4) 
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The patients whose HbA1c was studied; were divided in to two groups, one with 
HbA1c ≤7% and second with >7% in order to assess the relation between long 
term glycemic control and altered VEPs. (Table: 3,5-12 / fig:5-16 ).  
The results showed that P100 latencies were significantly prolonged in both 
GroupIIA5  and  GroupIIB5 patients whose HbA1c value is >7%.(Table - 3,5 & 9/ 
fig: 5,6,7,8,9 & 13 ). 
The N75 latencies in both GroupIIA5  and Group II B5 patients showed prolongation 
with poor glycemic control (HbA1c >7%) but the statistical significance could not 
be demonstrated. (Table:3,6 & 10 / fig: 5,6,7,8,10 & 14).  
The N145 latency and N 75- P100 amplitude in both GroupIIA5  and Group II B5   were 
not prolonged with poor glycemic control (HbA1c >7%). (Table -3,7,8,11 & 12/ 
fig: 11,12,15 & 16 ). A positive correlation was found between prolonged P100 
latencies and glycemic control in Group II A  and Group II B Patients, but, 
statistically  significant differences was not found  between these two groups in 
relation to glycemic  control.(Table - 3 / fig:5,6,7 & 8).  
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The  study groups were analysed to find out the correlation between  prolongation 
of VEP latencies and duration of diabetes. The mean value of the P100, N75, N145 
and N75-P100 amplitude were shown in(Table : 4 / fig : 17-21 ). 
The P100 latencies in Group II A  and Group II B showed siginificant delay with 
increased duration of diabetes(Table:4 / Fig: 17- 21 ). 
The N75, N145 latencies and N75-P100 amplitude values were not prolonged with 
increased duration of the disease (Table:4 / Fig: 17- 21). A positive correlation was 
found between prolonged P100 latencies and increased duration of disease but, 
there was no statistically significant difference  observed between Group IIA and  
Group II B in relation to duration of disease. (Table : 4 / Fig: 17- 21)                                        
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         TABLE: 1     P100, N75, N145 LATENCIES  AND N75-P100 AMPLITUDE IN GROUP I & GROUP II 
VEP 
PARAMETERS 
Group I Group IIA Group IIB P VALUE 
Right eye 
Mean± SD 
Left eye 
mean±SD 
Right eye 
Mean± SD 
Left eye 
mean±SD 
Right eye 
Mean± SD 
Left eye 
mean±SD 
Right 
Eye 
Left 
Eye 
P100 ≤100 97.9 ± 1.93 98.13±1.59 98.37±1.81 97.97±1.88 96.25±2.86 96.42±2.78 0.075 .057 
P100 >100 100.7±0.41 100.87±0.47 105.69±3.95 106.85±2.82 105.5±3.63 104.34±3.34 0.030 0.007 
N75 ≤75 71.13±3.20 70.32±3.09 71.20±4.09 71.16±3.74 69.43±4.62 67.83±3.07 0.330 0.028 
N75 >75 76.42±0.30 75.08±1.20 76.58±3.22 77.45±1.6 76.87±3.88 76.28±4.45 0.149 0.089 
N145 ≤145 135.19±5.49 133.15±6.19 136.09±5.64 134.88±5.88 134.34±7.41 133.65±7.64 0.076 0.080 
N145 >145 145.98±3.06 145.48±3.55 146.33±5.62 145.96±5.00 146.12±5.67 146.25±3.25 0.862 0.741 
N75-P100 ≤5 4.98±0.49 4.93±0.43 4.97±0.25 4.91±0.27 4.90±0.17 4.88±0.16 0.091 0.093 
N75-P100 >5 5.25±0.14 5.34±0.16 5.29±1.10 5.23±0.14 5.42±0.22 5.41±0.22 0.055 0.086 
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TABLE: 2 COMPARISON  OF VEP RESPONSES IN GROUP IIA AND GROUP IIB PATIENTS 
 Group IIA Group IIB P VALUE 
VEP 
PARAMETERS 
Right eye 
Mean± SD 
Left eye 
mean±SD 
Right eye 
Mean±SD 
Left eye 
mean±SD 
(Right) (left ) 
P100 ≤100 98.37±1.81 97.97±1.88 96.25±2.86 96.42±2.78 0.092 0.168 
P100 >100 105.69±3.95 106.85±2.82 105.5±3.63 104.34±3.34 0.907 0.082 
N75 ≤75 71.20±4.09 71.16±3.74 69.43±4.62 67.83±3.07 0.327 0.065 
N75 >75 76.58±3.22 77.45±1.6 76.87±3.88 76.28±4.45 0.707 0.330 
N145 ≤145 136.09±5.64 134.88±5.88 134.34±7.41 133.65±7.64 0.451 0.614 
N145 >145 146.33±5.62 145.96±5.00 146.12±5.67 146.25±3.25 0.862 0.741 
N75-P100 ≤5 4.97±0.25 4.91±0.27 4.90±0.17 4.88±0.16 0.614 0.08 
N75-P100 >5 5.29±1.10 5.23±0.14 5.42±0.22 5.41±0.22 0.165 0.6 
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TABLE: 3 COMPARING  VEP RESPONSES WITH HbA1C IN GROUP IIA AND GROUP IIB PATIENTS 
 Group IIA Group IIB P value 
 HbA1c≤ 7 HbA1c>7 HbA1c≤7 HbA1c>7 HbA1c≤7 HbA1c>7 
VEP 
WAVE 
FORMS 
Righteye 
Mean± SD 
Left eye 
mean±SD 
Right eye 
Mean± SD 
Left eye 
Mean±SD 
Righteye 
Mean± SD 
Left eye 
mean±SD 
Right eye 
Mean± SD 
Left eye 
mean±SD 
Righte
eye 
 
Left 
eye 
Right 
eye 
 
Left eye 
P100 99.46±2.18 99.54±3.51 107.72±3.19 106.72±4.04 98.17±3.81 98.44±3.76 107.21±3.54 105.11±4.35 0.316 0.045 0.776 0.471 
N75 72.98±5.17 72.42±4.41 77.47±5.12 76.34±3.15 71.83±4.99 71.69±5.22 76.07±8.39 77.11±10.82 0.576 .709 0.189 0.584 
N145 137.75±9.01 139.73±10.24 139.31±6.1 136.91±5.7 137.5±11.62 134.64±9.49 138.69±7.15 136.57±8.07 0.953 0.209 0.848 0.927 
N75- 
P100 
4.94±0.43 4.91±0.46 4.87±0.3 4.91±0.31 5.13±0.33 5.17±.034 5.07±0.31 5.04±0.29 0.253 0.123 0.224 0.428 
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TABLE: 4 DURATION OF DIABETES  AND WAVE PATTERNS OF VEP  IN GROUP IIA & IIB PATIENTS 
 
DURATION 
IN YEARS 
Group 
IIA 
Group 
IIB 
P value 
0-10 11-20 >20 0 -10 11 -20 >20 0 -10 11 -
20 
>20 
Mean± SD Mean± SD Mean± SD Mean± SD Mean± SD Mean± SD    
P100 100.21±3.35 102.58±2.22 107.37±3.10 98.8±3.64 101.46±5.16 107.29±5.72 0.319 0.253 0.965 
N75 74.15±5.38 76.78±4.62 76.76±3.93 72.36±3.42 77.14±7.51 75.5±2.45 0.315 0.053 0.901 
N145 140.79±10.43 132.79±5.74 141.03±5.59 141.43±9.28 132.0±8.83 139.25±6.34 0.871 0.794 0.528 
N75-P100 4.84±0.46 4.95±0.35 4.94±.035 5.14±0.40 5.08±0.22 4.87±0.13 0.085 0.071 0.661 
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TABLE NO: 5 
                       HbA1c level and P 100 latency in Group II A4  and Group II A5   
 
HbA1c 
Right eye Left eye 
< 100ms > 100ms < 100ms > 100ms 
  ≤   7.0  (12) 8 4 9 3 
> 7.0   (8) 0 8 1 7 
Mean 98.37 / 0 107.7/101.6 98.08/97.5 104.08/108.03 
SD 1.81 / 0 3.19/0.63 1.99/0 3.26/1.69 
‘p’ value  0.004 
Significant 
 0.031 
Significant 
 
                                                     TABLE NO: 6   
                   HbA1c level and  N 75 latency in Group II A4 and Group II A5    
 
HbA1c 
Right eye Left eye 
< 75ms > 75ms < 75ms > 75ms 
   ≤  7.0  (12) 8 4 9 3 
> 7.0   (8) 5 3 2 6 
Mean 70.53/80.95 73.0/77.87 70.94/72.13 76.86/77.75 
SD 4.47/3.58 2.64/1.88 4.06/2.29 1.09/1.82 
‘p’ value  0.456 
 Not 
Significant 
 0.472 
Not 
significant 
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TABLE NO: 7 
HbA1c level and N 145 latency in Group II A4 and Group II A5    
 
HbA1c 
Right eye Left eye 
< 145ms > 145ms < 145ms > 145ms 
  ≤  7.0  (12) 10 2 8 4 
> 7.0   (8) 7 1 7 1 
Mean 134.9/137.7 152/150 134.2/135.5 150.6/146.2 
SD 6.18/4.66 7.78/0 7.06/4.63 5.50/0 
‘p’ value  0.414 
Not 
significant 
 0.160 
Not 
significant 
 
                                                       TABLE NO: 8 
     HbA1c level and N75-P100 Amplitude in Group II A4  and Group II A5   
 
HbA1c 
Right eye Left eye 
< 5 μv > 5 μv < 5 μv > 5 μv 
  ≤ 7.0  (12) 6 6 6 6 
> 7.0   (8) 6 2 5 3 
Mean 4.59/4.74  4.53/4.70  
SD 0.27/0.23  0.32/0.18  
‘p’ value 0.313 
Not 
significant 
 0.312 
Not 
significant 
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TABLE NO: 9 
            HbA1c level and P 100 latency in Group II B4 and Group II B5    
 
HbA1c 
Right eye Left eye 
< 100ms > 100ms < 100ms > 100ms 
  ≤ 7.0  (13) 9 4 8 5 
> 7.0   (7) 0 7 1 6 
Mean 98.44/98.01 98.17/97.1 107.21/105.60 105.11/106.01 
SD 3.75/3.65 3.81/3.75 3.54/3.65 4.35/4.45 
‘p’ value  < 0.001 Significant 0.002  Significant 
 
TABLE NO: 10 
          HbA1c level and  N 75 latency in Group II B4  and Group II B5     
 
HbA1c 
Right eye Left eye 
< 75ms > 75ms < 75ms > 75ms 
  ≤ 7.0  (13) 10 3 10 3 
> 7.0   (7) 4 3 4 3 
Mean 71.82/70.50 73.07/72.58 71.69/75.05 74.11/75.05 
SD 4.99 8.39 5.22 10.82 
‘p’ value 0.680  Not significant 0.505 Not significant 
                                           
                                      
57 
 
TABLE NO: 11 
                     HbA1c level and N 145 latency in Group II B4  and Group II B5  
 
HbA1c 
Right eye Left eye 
< 145ms > 145ms < 145ms > 145ms 
 ≤ 7.0  (13) 10 3 11 2 
> 7.0   (7) 6 1 7 0 
Mean 137.50/140.5 138.64/135.5 134.63/135.5 136.57/135.65 
SD 11.62 7.15 9.49 8.07 
‘p’ value 0.816 Not significant 0.653 Not significant 
 
                                                    TABLE NO: 12 
     HbA1c level and N75-P100Amplitude in Group II B4  and Group II B5    
 
HbA1c 
Right eye Left eye 
< 5 μv > 5 μv < 5 μv > 5 μv 
   ≤ 7.0  (13) 8 5 6 7 
> 7.0   (7) 4 3 5 2 
Mean 5.13/4.90 5.07/5.12 5.17/4.85 5.04/4.95 
SD 0.33 0.31 0.34 0.29 
‘p’ value 0.711 Not significant 0.402 Not significant 
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 Fig: 1
P100,N75,N145 LATENCIES & N75-P100 AMPLITUDE IN 
GROUPI,II A & II B PATIENTS(RIGHT EYE)  
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Fig: 2
P100,N75,N145 LATENCIES & N75-P100 AMPLITUDE IN 
GROUPI,IIA & II B PATIENTS(LEFT EYE)
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 Fig - 3
P100,N75,N145 LATENCIES & N75-P100 AMPLITUDE IN 
GROUP II A & IIB PATIENTS(RIGHT  EYE)
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Fig:4
P100,N75,N145 LATENCIES & N75-P100 AMPLITUDE IN 
GROUP IIA &IIB PATIENTS(LEFT EYE)
0
20
40
60
80
100
120
140
160
GROUPIIA GROUPIIB
P100
N 75
N 145
N75-P100
 
Fig: 5
COMPARING VEP RESPONSES WITH  HbA1C>7IN 
GROUPIIA & IIB(RIGHT EYE)
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Fig: 6 
COMPARING VEP RESPONSES WITH HbA1C > 7 IN GROUP II A 
& II B (LEFTEYE)
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Fig -7
COMPARING VEP RESPONSES WITH HbA1C < 7 IN 
GROUP II A & II B (RIGHTEYE)
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Fig: 8
COMPARING VEP RESPONSES WITH HbA1C < 7 IN 
GROUP II A & II B (LEFTEYE)
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Fig: 17
DURATION Of DIABETES & VEP RESPONSES IN 
GROUP II A PATIENTS
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Fig: 18
DURATION Of DIABETES & VEP RESPONSES IN 
GROUP II BPATIENTS
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Fig: 19
VEP RESPONSES & 0- 10 YRS OF DURATION  IN 
GROUP II A & IIB PATIENTS
 
0
20
40
60
80
100
120
140
GROUP IIA GROUP IIB
P100
N 75
N 145
N75-P100
Fig: 20
VEP RESPONSES & 11 -20 YRS OF DURATION  IN 
GROUP II A & IIB PATIENTS
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Fig: 21
COMPARISON OF  VEP RESPONSES WITH  > 20 YRS OF 
DURATION  BETWEEN GROUP II A & IIB PATIENTS
 
  
  
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
    
DISCUSSION  
The present study was done on 40 diabetics and 40 controls in the age group of 30-
70 years. The P100 latencies of VEP were significantly delayed in Group IIA and 
Group IIB patients as compared to Group I subjects. This finding was consistent 
with the observations of Varkonyi T et al 
25
, Dolu H et al 
14
, Azal O et al 
42 
, 
Szabela D et al 
43
,  Li P et al 
44 
, Fierro B et al 
12 
, Parisi V et al
13 
, Karlika D et al
15 
,  
Verotti A et al 
24 
, Micheal Algan et al 
26 
, and Ziegler O et al 
27
 who reported 
similar changes in their study.The significant correlation of the delay in the P100 
latency with increased duration of diabetes , corroborated with the findings of Dolu 
H et al 
14 
, Azal O et al 
42 
 and  Li p et al 
44 
. A positive correlation was documented 
between glycemic control  and prolonged P100 latencies. This findings was 
consistent with the observations of      Sami ulus 
17 
, Pozzessere et al 
18 
. The N75 
and N145 latencies were not significantly delayed in Group IIA and Group IIB 
patients  as compared to Group I subjects.VEP responses were compared between 
Group IIA and Group IIB patients. No significant difference was found between 
these two groups. This finding  was consistent with the observations of Pozzessere 
G et al 
18 
. Comparison of VEP responses was done between Group IIA and Group 
IIB in relation to glycemic control and duration of disease.  
59 
No significant  difference was found  between  these  two groups. This findings  
was consistent with the observations  of Algan M et al 
26 
. 
The P100 wave form is generated in striate and  peri striate occipital cortex due to 
activation of primary visual cortex and also due to the discharge of thalamo 
cortical fibres. N75 reflects the activity of fovea and primary visual cortex, while 
N145 reflects the activity of the visual association area. The P100 is a prominent 
peak that shows relatively little variation between the subjects, minimal with in 
subject‟s interocular difference, and minimal variation with repeated measurements 
overtime. Our findings signify that there is a definite neurological deficit in 
diabetes mellitus. The exact pathophysiology of optic neuropathy is not clear, but it 
seems to be multifactorial involving metabolic and vascular factors. The possible 
mechanisms for the development of optic nerve dysfunction are  
1) Polyol pathway.  
2) Vessel ischaemia. 
Polyol pathway: The polyol pathway refers to the intra cellular mechanisms 
responsible for changing the number of hydroxyl units on a glucose molecule. In 
the sorbitol pathway, glucose is first transformed to sorbitol and then to fructose.  
60 
This process is activated by the enzyme aldose reductase. Although glucose is 
converted readily to sorbitol, the rate at which sorbitol can be converted to fructose 
and then metabolized is limited. Sorbitol is an osmotically active, and it has been 
hypothesized that the presence of excess intra cellular amounts may alter the cell 
function in nerves and blood vessels. Increased sorbitol is also associated with a 
decrease in myoinositol and reduced ATPase activity in axons. The reduction of  
these compounds may contribute to the pathogenesis of optic nerve fibre loss. 
Vessel ischaemia: 
Thickening of the walls of nutrient vessels that supply the nerve leads to  vessel 
ischaemia may contribute to the development of segmental demyelination. This 
process is accompanied by a slowing of nerve conduction. 
Neuropoietic cytokines including interleukin-1(IL-1), IL-6, leukemia inhibitory 
factor (LIF), ciliary neuro-trophic factor(CNTF), tumour necrosis factor 
alpha(TNF-alpha), and transforming growth factor beta(TGF-beta), exibit 
pleiotrophic effects on the homeosatsis of the glia and on the neurons in the 
central, peripheral and the autonomic nervous systems. These cytokines are 
produced locally by the resident and infiltrating macrophages, lymphocytes, mast 
cells,  fibroblasts  and  sensory neurons. The  accumulation of  these  mediators  
61 
probably delays the conduction in the visual pathway, which could  be the probable 
cause of the delay in the P100 latency which was  found in the Group IIA and IIB as 
compared to the Group I subjects. With the increase in duration of diabetes, the 
accumulation of these mediators also increases, which can cause further delay in 
the latencies in diabetics with more duration of disease as compared to diabetics 
with a lesser duration of the disease. 
The delayed P100 latencies which were recorded in the absence of retinopathy are 
indicative of anterior visual pathway affection in diabetics and it is an expression 
of structural damage at the level of myelinated optic nerve fibres. P100 latencies 
were observed to be more prolonged in those  who had poor glycemic control as a 
result of more prolonged exposure to toxic metabolites. 
The progressive increase in P100 latency values are a direct sign of retinal 
ganglion cell damage, which takes place even before the first ophthalmoscopically 
detectable signs of diabetic retinopathy arise.  
Therefore VEP should be considered as a valid method for detecting prediabetic 
retinopathy, which could contribute greatly to the prevention of diabetic 
retinopathy and its complications. 
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SUMMARY 
& 
CONCLUSION 
 
 
 
 
 
 
 
SUMMARY 
 The visual evoked responses was studied in both type1 and type 2 diabetic 
patients as well as in normal subjects.  
 The P100 latency was significantly delayed in both type 1 and type 2 
diabetic patients as compared to the normal subjects. 
 A positive correlation was documented between prolonged P100 latencies 
and increased duration of diabetes. 
 The P100 latency was significantly delayed in those patients who had poor 
long term glycemic control . 
 The delay in N75, N145 latencies and decrease in N75-P100 amplitude 
values were not  statistically significant in diabetics as compared to control 
subjects. 
 VEP responses were compared between type1 and type 2 diabetes.There was 
no statistically significant difference  observed between these two groups. 
 VEP responses were compared between type1 and type 2 diabetes in relation 
to glycemic control & duration of disease. No statistically significant 
difference  was observed between these two groups. 
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CONCLUSION 
The delay in P100 latency was observed in diabetic patients before the development 
of overt retinopathy. The possible mechanisms for the development of optic nerve 
dysfunction which could  lead on to delay in P100 latencies could be due to  
 Increased intracellular sorbitol level 
 Reduced myoinositol and ATPase activity 
 Vessel ischemia 
 Accumulation of IL-1,IL-6,Leukemia inhibitory factor, ciliary neuro-tropic 
factor (CNTF), tumour necrosis factor alpha  and  transforming growth 
factor beta 
 Structural damage at the level of  myelinated optic nerve fibres 
 Retinal ganglion cell damage 
So, VEP measurement which is a highly sensitive, reliable, non invasive and 
reproducible method for detecting the early alterations in the central optic 
pathways in diabetics. It should be recommended whenever possible and this must 
be added to the list of screening tools for a more complete and early assessment of 
neurological involvement of the diabetic patients to advise them for an early and 
proper management of the disease.  
64 
GLYCEMIC CONTROL : 
The Diabetes Control and Complications Trial (DCCT) provided definitive proof 
that reduction in chronic hyperglycemia can prevent many of the early 
complications of DM. The DCCT demonstrated that improvement of glycemic 
control reduced nonproliferative and proliferative retinopathy (47% reduction). 
Improved glycemic control also slowed the progression of early diabetic 
complications. The benefits of an improvement in glycemic control occurred over 
the entire range of HbA1C values, suggesting that at any HbA1C level, an 
improvement in glycemic control is beneficial. The goal of therapy is to achieve an 
HbA1C level as close to normal as possible, without subjecting the patient to 
excessive risk of hypoglycemia.                                                                                         
The most effective therapy for diabetic retinopathy is prevention. Intensive 
glycemic control will delay the development or slow the progression of retinopathy 
in individuals with either type 1 or type 2 DM. Regular, comprehensive eye 
examinations are essential for all individuals with DM. Most diabetic eye disease 
can be successfully treated if detected early.  
 
65 
LIMITATIONS OF THE STUDY: 
The present study was a basic screening of diabetic individuals for optic nerve 
dysfunction. A larger sample size and a longitudinal study will be of great value to 
demonstrate whether a good glycemic control would reverse the structural 
abnormalities of the optic nerve. 
FUTURE SCOPE OF THE PRESENT STUDY: 
The current study is of public health importance as it suggests that by screening for 
and detecting optic neuropathy, physician can advice patients regarding glycemic 
control of diabetes and prevention of retinopathy. 
This study can be further extended to involve a larger sample from a group of 
population.  
Further studies are needed to determine  whether  a  good glycemic control  would 
reverse  the structural  abnormalities  of  the  optic nerve or  prevent the early 
progression of diabetic retinopathy. 
Further studies are essential to determine whether short-term strict control of blood 
glucose can improve abnormal visual evoked potentials (VEPs) in poorly 
controlled diabetic patients with no overt diabetic complications.  
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ANNEXURES 
 
  
CONSENT FORM 
Dr.S.Navurang, Post graduate student in the Department of Physiology, 
Coimbatore Medical College, Coimbatore is studying the visual evoked potentials 
in diabetes mellitus. The procedure of recording of visual evoked potential, 
collection of blood specimen  for HbA1C were explained to  me clearly. I 
understand that there are no risks  involved  in  the  above  procedure. I  hereby 
give my consent  to  participate in  this  study. The  data  obtained  herein  may be 
used for research and publication. 
 
Signature :  
Name :  
Place : 
  
VISUAL EVOKED POTENTIALS IN DIABETES MELLITUS 
NAME: 
AGE: 
SEX: 
OCCUPATION: 
ADDRESS: 
PRESENT HISTORY: 
          HISTORY OF DIABETES: YES/ NO 
           DURATION OF DIABETES: 
PAST HISTORY: 
           HISTORY OF HYPERTENSION: YES/ NO 
           HISTORY OF CORONARY ARTERY DISEASE: YES/ NO 
           HISTORY OF GLAUCOMA AND  CATARACT: YES/ NO 
FAMILY HISTORY: 
            FAMILY HISTORY OF DIABETES/ HYPERTENSION: YES/ NO 
VITAL SIGNS: 
          BLOOD PRESSURE : 
           PULSE RATE: 
           RESPIRATORY RATE: 
CLINICAL EXAMINATION : 
           CVS: 
            RS: 
            ABDOMEN: 
             CNS: 
OCULAR EXAMINATION: 
             CATARACT : PRESENT/ ABSENT 
              INTRA OCULAR TENSION: NORMAL / INCREASED 
INVESTIGATIONS: 
             FASTING BLOOD SUGAR: 
             POSTPRANDIAL BLOOD SUGAR: 
           HbA1C  LEVEL: 
 VISUAL EVOKED RESPONSE: 
                P100  LATENCY: NORMAL/ DELAYED 
                N75  LATENCY: NORMAL/ DELAYED 
                N145  LATENCY: NORMAL/ DELAYED 
                N75-P100 AMPLITUDE: NORMAL/ DECREASED 
 
 
 
 
 
 
            
 
  
Master chart -Group II A : Visual evoked responses in Type I Diabetes mellitus 
 
S.NO 
 
Age 
Blood sugar  
HbA1C 
 
Duration 
Right eye Left eye 
FBS 
(mg/dl) 
PPBS 
(mg/dl) 
N75 
(msec) 
P100 
(msec) 
N145 
(msec) 
N75-
P100µv 
N75 
(msec) 
P100 
(msec) 
N145 
(msec) 
N75-
P100µv 
1 50 130 209 7.9 25 75 106.5 138.5 4.58 76.25 107.5  4.64 
2 45 113 143 6.5 16 75 100 132.5 5.2 74.5 96.5 130.5 5.4 
3 52 178 278 8.2 21 74 112 150 5 76 108 139.5 5.2 
4 46 99 165 6 17 73.5 98.5 135 5.2 75.6 98.75 130 5.4 
5 55 78 207 8.1 24 85 112.5 143.75 4.84 77.5 110 146.25 4.72 
6 42 129 198 7.1 12 78.5 103.75 130 5 73.75 97.5 128.5 5 
7 33 112 142 6.5 8 66.5 95 125 5.4 65 95 127.5 5.2 
8 52 268 179 6.8 23 73.75 102.5 133.75 5.48 75 107.5 148.75 5.32 
9 53 128 210 6.2 9 78.5 100 143.75 5.24 70 98.5 142.75 5.14 
10 51 140 216 7.5 23 76.25 105.5 138.5 4.58 80 108.75 138.5 4.64 
11 56 401 260 6.9 6 77.5 100 157.5 4.21 77.5 101 158.75 4.32 
12 58 249 390 7.5 21 81.5 108.5 142.5 5.2 80 110 140.5 5.2 
13 32 130 218 6.1 14 68.5 96.5 132.5 5 71.5 95 128.5 5 
14 42 105 218 6.5 26 80 101.5 146.5 4.8 77.5 103.75 146.5 4.28 
15 47 197 283 6.4 18 70 98.5 127.5 4.53 73.5 100 130 4.88 
16 48 88 217 6.9 3 75.5 101 140 5.34 75 99.5 148.5 5.28 
17 50 190 315 7.5 21 70 108 134.75 5.28 70.5 105.5 130.75 5.33 
18 40 128 216 6.4 15 62.5 98.5 143.5 4.48 64.5 99.5 145 4.32 
19 55 390 249 7.8 8 83.5 105 136.5 4.48 76.75 106.5 133.75 4.52 
20 38 130 218 6.7 8 74.5 101.5 135.5 4.53 69.5 107.5 137.5 4.64 
 
 
 
                                 Master chart -Group II B : Visual evoked responses in Type II Diabetes mellitus 
 
S.NO 
 
Age 
Blood sugar  
HbA1C 
 
Duration 
Right eye Left eye 
FBS 
(mg/dl) 
PPBS 
(mg/dl) 
N75 
(msec) 
P100 
(msec) 
N145 
(msec) 
N75-
P100µv 
N75 
(msec) 
P100 
(msec) 
N145 
(msec) 
N75-
P100µv 
1 65 317 459 7.8 12 78.5 107.5 140 5.65 87.5 102.5 142.5 5.65 
2 42 175 263 6 8 67.5 97.5 138.5 4.46 71.5 101.5 138.5 4.48 
3 43 132 188 6.2 6 77.5 102.5 138.75 5 77.5 100 135 5.2 
4 57 140 176 6.8 13 76.25 93.75 127.5 5.42 76.25 95 127.5 5.42 
5 50 204 306 7 11 78.5 102.5 125.5 5.4 81.5 101.5 122.5 5.4 
6 48 241 339 7.5 22 62.5 105.5 135.5 5 62.5 98.5 128.5 5 
7 42 167 315 7.4 14 76 105 130 5.2 82.5 102.5 123.75 5 
8 58 162 287 7 7 72.5 102.5 123.75 5 72.5 102.5 123.75 5 
9 50 208 367 8.1 25 67.5 106.25 145 4.68 67.5 106.5 145 4.78 
10 67 150 221 6.5 18 72.5 95 130 5 67.5 93 127.5 5 
11 66 210 335 8.1 6 86.5 105 148.5 5.17 86.25 107.5 133.75 5.12 
12 47 130 307 6.9 21 75 100 160 5.8 70 101.5 150 5.8 
13 55 124 194 6.8 9 72.5 102.5 152.5 5.38 71.5 103.5 150.5 5.38 
14 59 152 296 7 17 66.5 93.75 122.5 5 66.25 92.5 122.5 5 
15 48 131 212 6.9 8 72.5 100 141.5 5.31 65 97.5 140 5.21 
16 65 402 465 8.2 6 65.5 115 141.5 4.9 67.5 112 140 4.9 
17 46 159 313 6.5 14 72.5 92.5 135 5 70 95 140 5 
18 37 231 198 7.9 13 75 106.25 130 4.9 65 106.25 142.5 4.8 
19 47 109 280 6.5 22 70 98.75 147.5 5 77.5 100 136.25 5.48 
20 58 235 180 7 7 60 95 144.5 4.9 65 96.25 136.25 4.8 
 
 
 
 
Master chart –Group I : Visual evoked responses in control subjects 
 
S.NO 
 
Age 
Blood sugar Right eye Left eye 
FBS 
(mg/dl) 
PPBS 
(mg/dl) 
N75 
(msec) 
P100 
(msec) 
N145 
(msec) 
N75-
P100µv 
N75 
(msec) 
P100 
(msec) 
N145 
(msec) 
N75-
P100µv 
1 50 87 122 72.5 97.5 126.25 5.2 71.5 98.5 127.75 5.4 
2 45 89 145 73.75 100 126.25 5.2 73.75 98.75 126.25 5 
3 52 92 160 75 100 140.5 5.47 73.5 101.5 138.5 5.5 
4 46 100 167 76.25 98.75 140.5 5 75 98 138.5 5 
5 55 98 154 72.5 97.5 140.5 5 76.25 98.75 145 4.8 
6 42 78 160 73.75 97.5 140.5 5 76.5 98.75 131 5.2 
7 33 89 145 75 95.5 125 5.10 66.5 97.5 140.5 5.48 
8 52 99 156 76.25 100.25 145 5.28 76.25 97.5 141.5 5.25 
9 53 90 145 76.5 98.75 132.5 5 73.75 97.5 132 5 
10 60 78 130 66.25 90 137.5 5 67.5 91 120 5 
11 56 86 139 76.25 97.5 137.5 5.2 65 98.75 137 5.4 
12 58 98 156 73.75 95.5 132.5 5 63.75 97.5 145 5.4 
13 32 90 165 67.5 100 140 5 76.25 98.75 133.75 5.2 
14 42 95 170 65 97.5 135 5.4 73.75 96.25 132.5 5 
15 47 95 175 63.75 97.5 131.25 5.2 67.5 98.75 127.5 5.4 
16 48 91 178 76.25 95 131.25 5.4 72.5 97.5 145 5.3 
17 50 91 165 73.75 97.5 141.25 5.24 75 97.75 120 5.28 
18 40 97 178 67.5 97.5 123.5 5.2 78.75 100 125.5 5.4 
19 55 96 177 73.75 101.25 123.75 5 78.5 98.75 137.5 5 
20 38 80 156 73.75 98 137.5 5.1 71.25 97 141 5.2 
 
                                  
Master chart –Group I :Visual evoked responses in control subjects 
 
 
S.NO 
 
Age 
Blood sugar Right eye Left eye 
FBS 
(mg/dl) 
PPBS 
(mg/dl) 
N75 
(msec) 
P100 
(msec) 
N145 
(msec) 
N75-
P100µv 
N75 
(msec) 
P100 
(msec) 
N145 
(msec) 
N75-
P100µv 
21 35 89 139 70 99.5 137.5 5.5 70 99.5 128.5 5.3 
22 40 86 156 67 98 138.5 5 67 98 130 4.2 
23 55 98 165 75 97 139 5.1 75 97 128.5 4.12 
24 50 90 170 71 98.5 140 5.1 71 98.5 131.5 4.6 
25 40 95 175 70 96 139.5 4.1 70 96 129 4.12 
26 38 95 178 65 100 140 4 65 100 129.75 4.18 
27 60 91 165 69 101 138 4.1 69 101 138 4 
28 58 91 178 71 100.5 137.5 3.9 71 100.5 135.5 4.5 
29 52 97 177 71 99 139.5 3.8 71 99 138.5 4 
30 53 96 156 71 99.5 131.75 4 71 99.5 135 4.7 
31 43 86 122 72.5 98 131.5 4.2 72.5 98 128 4.7 
32 54 98 145 74 98.5 138 4.1 74 98.5 136 3.8 
33 42 90 160 70.5 97.5 137 4.28 70.5 97.5 130.5 3.9 
34 57 95 167 68.5 98.5 136.5 4.2 68.5 98.75 128.5 3.92 
35 39 95 154 69.5 98.75 135.5 3.9 69.5 98.75 131.5 4.8 
36 50 91 160 67 100 137 3.8 67 100 131.5 4.4 
37 48 91 145 71 100.5 137 3.9 71 100.5 138.5 3.9 
38 40 97 156 69 99.5 130 3.92 69 99.5 131.5 4.12 
39 38 96 145 72 99.75 130.5 4.12 72 99.75 129.5 4.12 
40 53 80 130 66.5 97 125.5 4.21 66.5 97 130.5 4.2 
 
